Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | -$1.40 | -$1.40 | -$1.40 |
Q2 2024 | 3 | -$1.47 | -$1.47 | -$1.47 |
Q3 2024 | 3 | -$1.31 | -$1.31 | -$1.31 |
Q4 2024 | 5 | -$1.48 | -$1.09 | -$1.36 |
Q1 2025 | 3 | -$1.52 | -$1.17 | -$1.35 |
Q2 2025 | 2 | -$1.41 | -$1.41 | -$1.41 |
Q3 2025 | 2 | -$1.32 | -$1.32 | -$1.32 |
Q4 2025 | 2 | -$1.23 | -$1.23 | -$1.23 |
Adverum Biotechnologies, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $-1.3 earnings per share for the quarter, missing analysts' consensus estimates of $-1.2 by $0.1. The company had revenue of 1.00 M for the quarter and had revenue of 3.60 M for the year. Adverum Biotechnologies, Inc. has generated $-12 earnings per share over the last year ($-11.62 diluted earnings per share) and currently has a price-to-earnings ratio of -1.05. Adverum Biotechnologies, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | -$1.20 | -$1.30 | -0.1 | $125,000 | $1.00 M |
08/12/2024 | Q2 2024 | -$1.27 | -$0.89 | 0.38 | $106,000 | $0 |
05/09/2024 | Q1 2024 | -$1.28 | -$1.50 | -0.22 | $0 | |
03/18/2024 | Q4 2023 | -$2.80 | -$2.34 | 0.46 | $-3,600,000 | |
11/09/2023 | Q3 2023 | -$3.00 | -$3.26 | -0.26 | $0 | |
08/10/2023 | Q2 2023 | -$3.20 | -$3.13 | 0.07 | $0 | |
05/11/2023 | Q1 2023 | -$2.90 | $3.60 M | |||
03/30/2023 | Q4 2022 | -$3.20 | -$3.28 | -0.08 | $0 | |
11/10/2022 | Q3 2022 | -$3.20 | -$0.40 | 2.8 | $0 | |
08/11/2022 | Q2 2022 | -$3.80 | -$0.44 | 3.36 | $0 | |
05/12/2022 | Q1 2022 | -$3.40 | -$0.38 | 3.02 | $0 | |
03/29/2022 | Q4 2021 | -$4.20 | -$0.35 | 3.85 | $-7,500,000 | |
11/04/2021 | Q3 2021 | -$4.20 | -$0.39 | 3.81 | $0 | |
08/05/2021 | Q2 2021 | -$3.70 | -$0.45 | 3.25 | $0 | |
05/06/2021 | Q1 2021 | -$3.80 | -$0.29 | 3.51 | $7.50 M | |
03/01/2021 | Q4 2020 | -$3.20 | -$0.39 | 2.81 | $0 | |
11/05/2020 | Q3 2020 | -$3.50 | -$0.31 | 3.19 | $76,667 | $0 |
08/10/2020 | Q2 2020 | -$3.00 | -$0.36 | 2.64 | $76,667 | $0 |
05/28/2020 | Q1 2020 | -$2.70 | -$0.31 | 2.39 | $0 | |
03/12/2020 | Q4 2019 | -$3.10 | -$0.26 | 2.84 | $-250,000 |
Adverum Biotechnologies, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based off last year's report dates.
The conference call for Adverum Biotechnologies, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Adverum Biotechnologies, Inc.'s latest earnings report can be read online.
Adverum Biotechnologies, Inc. (:ADVM) has a recorded annual revenue of $3.60 M.
Adverum Biotechnologies, Inc. (:ADVM) has a recorded net income of $3.60 M. Adverum Biotechnologies, Inc. has generated $-11.62 earnings per share over the last four quarters.
Adverum Biotechnologies, Inc. (:ADVM) has a price-to-earnings ratio of -1.05 and price/earnings-to-growth ratio is -0.04.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED